Abstract
Abstract Background ALCAM (CD166) is a transmembrane; it has a role in the adhesion and binding of hematopoietic cells. It increases in different solid malignancies and hematological malignancies as multiple myeloma and acute leukemia. CD166 is considered one of the cancer stem cell markers responsible for most cancer recurrences following chemotherapy. Aim The study aimed to assess the expression of CD166 level in adult Egyptian acute lymphoblastic leukemia (ALL) patients, its correlation with disease-free survival, overall survival and relapse rate, as well as correlation with disease prognosis and response to treatment. Patients and methods This was a prospective cohort study conducted on 40 newly diagnosed ALL patients who will be recruited from the Clinical Hematology Department at Ain Shams University Hospital before initiation of chemotherapy in comparison to 15 patients in the control group. Results In comparison between newly diagnosed ALL patient initiation of chemotherapy and control groups, CD166 is elevated in ALL and has high sensitivity and specificity as a diagnostic and prognostic marker for ALL (P=0.000) and ALL patients with a high CD166 score have a higher overall survival rate. Conclusion ALL patients with a high CD166 score have a higher overall.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
